Serial 90769018
Live / Registered — Registered (as of 02 Aug 2022)
What this means for you
Registered since 02 Aug 2022. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 90769018
- Registration number
- 6810414
- Mark type
- Design / logo
- Filed
- 11 Jun 2021
- Published for opposition
- 12 Oct 2021
- Registered
- 02 Aug 2022
- Attorney of record
- Maury M. Tepper, III
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations, namely, for the activation of PKR (pyruvate kinase R), for the activation of PKM2 (pyruvate kinase isozyme M2), and for the prevention and treatment of blood disorders, pyruvate kinase deficiency (PKD), genetically defined diseases affecting red blood cells, hemolytic anemia
Owner
- Agios Pharmaceuticals, Inc., Cambridge, MA, US
- Agios Pharmaceuticals, Inc., Cambridge, MA, US
- Agios Pharmaceuticals, Inc., Cambridge, MA, US
Prosecution history
- 02 Aug 2022 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 02 Aug 2022 — REGISTERED-PRINCIPAL REGISTER
- 28 Jun 2022 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 26 Jun 2022 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 11 Jun 2022 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 10 Jun 2022 — STATEMENT OF USE PROCESSING COMPLETE
- 02 Jun 2022 — USE AMENDMENT FILED
- 10 Jun 2022 — SOU EXTENSION 1 GRANTED
- 02 Jun 2022 — SOU EXTENSION 1 FILED
- 10 Jun 2022 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 02 Jun 2022 — SOU TEAS EXTENSION RECEIVED
- 02 Jun 2022 — TEAS STATEMENT OF USE RECEIVED
- 09 Feb 2022 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
- 09 Feb 2022 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 09 Feb 2022 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED